Question to the Ministry of Justice:

To ask the Secretary of State for Justice, what steps he is taking to promote the use of long-acting injectable buprenorphine (LAIB) in i) sentencing decisions in cases involving opioid abuse ii) prison-release pathways in Hampshire.

Treatment and clinical prescribing decisions are the responsibility of services commissioned by NHS in prisons and local authority service providers in the community.

Responsibility for continuity of care for prison leavers, including access to medications and clinical care rests with prison drug and alcohol treatment providers liaising with community treatment providers.

The promotion of one medicine over another is strictly regulated in England and Wales.